

Biophytis Withdraws Registration Statement for Global Offering

Paris (France), Cambridge (Massachusetts, United States), July 25, 2019, 7:30 am CET – Biophytis (Euronext Growth Paris: ALBPS) (“Biophytis” or the “Company”), a clinical-stage biotechnology company focused on the development of therapeutics for age-related diseases, today announced that the Company has submitted a request to the U.S. Securities and Exchange Commission (the “SEC”) to withdraw its registration statement on Form F-1 (File No. 333-231655) (the “Registration Statement”) on file with the SEC and that it will postpone its proposed Nasdaq listing due to unfavorable market conditions. The Registration Statement has not been declared effective by the SEC and no securities have been sold in connection with the global offering described in the Registration Statement. The Company intends to consider other financing options.

The Phase 2b clinical trial (SARA-INT) of Sarconeos (BIO101) for the treatment of sarcopenia continues its development and recruitment as planned. For Sarconeos (BIO101) in Duchenne muscular dystrophy (DMD), Biophytis plans to submit an Investigational New Drug (IND) application to the FDA and clinical trial applications to the applicable regulatory agencies in Europe in the second half of 2019. The development of the Company’s preclinical research platform on retinopathies and other new and on-going research and development activities are continuing.

This press release does not, and is not intended to, constitute an offer to sell or the solicitation of an offer to buy securities, and shall not constitute an offer, solicitation or sale in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of that jurisdiction.

About Biophytis

Biophytis is a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes and improve functional outcomes for patients suffering from age-related diseases. Our therapeutic approach is aimed at targeting and activating key biological resilience pathways that can protect against and counteract the effects of the multiple biological and environmental stresses that lead to age-related diseases. Our lead drug candidate, Sarconeos (BIO101), is an orally administered small molecule in development for the treatment of neuromuscular diseases, including sarcopenia and Duchenne muscular dystrophy (DMD). Our second drug candidate, Macuneos (BIO201), is an orally administered small molecule in development for the treatment of retinal diseases, including dry age-related macular degeneration (AMD) and Stargardt disease. Biophytis is headquartered in Paris, France, and has offices in Cambridge, Massachusetts. The Company’s ordinary shares are listed on Euronext Growth Paris (Ticker: ALBPS - ISIN: FR0012816825). For more information please visit www.biophytis.com.

Disclaimer

This press release contains forward-looking statements. Forward-looking statements include all statements that are not historical facts. In some cases, you can identify these forward-looking statements by the use of words such as "outlook," "believes," "expects," "potential," "continues," "may," "will," "should,"



"could," "seeks," "predicts," "intends," "trends," "plans," "estimates," "anticipates" or the negative version of these words or other comparable words. These forward-looking statements include any statements regarding the Company's clinical programs and plan and potential financing and strategic options. Such forward-looking statements are subject to various risks and uncertainties including, without limitation, risks inherent in the development and/or commercialization of potential products, the outcome of its studies, uncertainty in the results of pre-clinical and clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights and those discussed in the Company's registration document and other regulatory filings with the French Autorité des Marchés Financiers (AMF), which are available on the AMF website (www.amf-france.org) and at www.Biophytis.com. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in such regulatory filings. We undertake no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise, except as required by law.

No communication or information relating to the Global Offering by Biophytis may be transmitted to the public in a country where there is a registration obligation or where an approval is required. The issuance or the subscription of the securities of the Company may be subject to legal and regulatory restrictions in certain jurisdictions; none of Biophytis and the banks involved in the Global Offering assumes any liability in connection with the breach by any person of such restrictions.

This press release is not a prospectus within the meaning of Directive 2003/71/EC of the European Parliament and the Council of 4 November 2003, as amended or superseded including by Directive 2010/73/EU and as implemented in each member state of the European Economic Area, and of EU Regulation 2017/1129 (the "Prospectus Regulations").

This press release and the information contained herein do not, and are not intended to, constitute an offer to sell or a solicitation of an offer to buy or subscribe to securities of Biophytis in any country. This press release is not an offer to the public, an offer to subscribe or designed to solicit interest for purposes of an offer to the public in any jurisdiction, including France.

Biophytis Investor Relations Contact

Daniel Schneiderman, CFO
dan.schneiderman@biophytis.com
Tel: +1 (857) 220-9720

U.S. Media Contact

LifeSci Public Relations
Cherilyn Cecchini, M.D.
cecchini@lifescipublicrelations.com
Tel: +1 (646) 876-5196

Europe Media Contact

Citigate Dewe Rogerson
Laurence Bault / Quentin Dussart
biophytis@citigatedewerogerson.com
Tel: +33 (0) 1 53 32 84 78 / +33 (0)1 55 30 70 91